pulseline logo

New theatre investment improves surgical outcomes

[vc_row][vc_column][vc_column_text]The Olympus VISERA ELITE II System with 4K, 3D and Infrared surgical modes are designed to increase accuracy, speed and precision during surgery and have been made available in eight of the hospitals 16 theatres.

Seven of these are mobile, meaning they can be moved to each specialist theatre and one is fixed and offers 4K, 3D and Infrared (IR) capabilities.

The system offers different observation possibilities such as narrow band imaging and infrared imaging. Infrared imaging is particularly important for gynaecological oncology procedures such as sentinel lymph node mapping, colorectal liver metastases and biliary identification during laparoscopic cholecystectomy.

The hospital has also acquired an additional system – the Olympus 4K System.

The Olympus 4K surgical platform to be used for primary and revisional laparoscopic procedures, offers true 4K image quality at four times the resolution of Full HD and utilises a wider colour gamut (BT2020) with over one billion colour combinations allowing for greater accuracy, speed and precision during surgery.

Improved patient outcomes

Perioperative Services Manager Dave Ramsay said the two new systems will be used for a range of surgical procedures in the areas of Upper GI, Bariatric, Colorectal, General, Gynaecology, Cardio Thoracic and ENT.

“Having the cutting-edge laparoscopic systems in our theatres means surgeons have the ultimate view of their surgical field,” he said.

“As one surgeon aptly put it, it means they have a view of open surgery combined with the magnification of a telescope.”

CEO, Ben Edwards said investing in the latest technologies was imperative for patient care.

“We are proud to have such highly-skilled specialists using these cutting-edge technologies across the hospital and we will continue to invest in future medical technologies which support improved patient outcomes,” he said.[/vc_column_text][/vc_column][/vc_row]

Related Stories

Featured, Future of MedTech

You have subscribed